Coronavirus / Paxlovid Pill is 90% effective

Doctors of the Therapeutic Clinic of the School of Medicine of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Panos Malandrakis, Giannis Danasis and Thanos Dimopoulos (Rector of EKPA) present the latest data.

The latest announcement states that the pill’s effectiveness in reducing morbidity and mortality reached 90% when given three to five days after the onset of symptoms, while the first data show an effectiveness against the Omicron type. ““The emergence of the new species has increased the need for treatment options for those who come in contact with the virus, and the adoption of this drug will make it an additional weapon in the fight against the pandemic.” says A. Burla, CEO of Pfizer.

Two antiviral pills from Pfizer and Merck have been submitted to the FDA for approval and a formal decision is expected by the end of the year. Preliminary data on the micron strain show its rapid prevalence in South Africa and some European countries, while it has already been discovered in 31 US states, with some initial data showing possible strain resistance to antibodies. monoclonal that have already been adopted.

The Regeneron company, whose monoclonal antibody has been approved, is already reporting potential reduced efficacy against the new omicron strain, while a new generation of drugs specifically targeted at the new strain is already being prepared. Another publication says that the micro strain escapes the immunity provided by the antibodies of Regeneron, Eli Lilly and AstraZeneca, which have received FDA approval for people whose immune system does not respond to the vaccine.

In another announcement by Pfizer the drug Paxlovid while not reducing symptoms in those at low risk for severe COVID-19 disease, it lowered viral load levels and reduced the already low risk of hospitalization and death in this subgroup, by including those who had been vaccinated and had at least one risk. factor for serious illness.

top channel